메뉴 건너뛰기




Volumn 19, Issue 12, 2010, Pages 1527-1544

Therapeutic potential of new second generation antipsychotics for major depressive disorder

Author keywords

augmentation; major depressive disorder; second generation antipsychotic; treatment resistant depression

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; CITALOPRAM; DOPAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LITHIUM ACETATE; MIRTAZAPINE; NEFAZODONE; NORADRENALIN; NORTRIPTYLINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

EID: 78649515965     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.538048     Document Type: Review
Times cited : (13)

References (111)
  • 1
    • 0037831023 scopus 로고    scopus 로고
    • The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R)
    • Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
    • (2003) JAMA , vol.289 , pp. 3095-105
    • Kessler, R.C.1    Berglund, P.2    Demler, O.3
  • 3
    • 0037493499 scopus 로고    scopus 로고
    • Cost of lost productive work time among US workers with depression
    • Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA 2003;289:3135-44
    • (2003) JAMA , vol.289 , pp. 3135-44
    • Stewart, W.F.1    Ricci, J.A.2    Chee, E.3
  • 4
    • 64949165379 scopus 로고    scopus 로고
    • Treatment-resistant depression and mortality after acute coronary syndrome
    • Carney RM, Freedland KE. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry 2009;166:410-17
    • (2009) Am J Psychiatry , vol.166 , pp. 410-17
    • Carney, R.M.1    Freedland, K.E.2
  • 5
    • 34248381347 scopus 로고    scopus 로고
    • Definition, assessment, and staging of treatment-resistant refractory major depression: A review of current concepts and methods
    • Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54
    • (2007) Can J Psychiatry , vol.52 , pp. 46-54
    • Berlim, M.T.1    Turecki, G.2
  • 7
    • 33751338530 scopus 로고    scopus 로고
    • Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report
    • Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
    • (2006) Am J Psychiatry , vol.163 , pp. 1905-17
    • Rush, A.J.1    Trivedi, M.H.2    Wisniewski, S.R.3
  • 8
    • 33749049165 scopus 로고    scopus 로고
    • A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report
    • quiz 665
    • Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;16:1519-1530; quiz 665
    • (2006) Am J Psychiatry , vol.16 , pp. 1519-1530
    • Nierenberg, A.A.1    Fava, M.2    Trivedi, M.H.3
  • 9
    • 85047695030 scopus 로고    scopus 로고
    • A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report
    • Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-72
    • (2006) Am J Psychiatry , vol.163 , pp. 1161-72
    • Fava, M.1    Rush, A.J.2    Wisniewski, S.R.3
  • 10
    • 66249105682 scopus 로고    scopus 로고
    • Utility of atypical antipsychotics in the treatment of resistant unipolar depression
    • DeBattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009;23:369-77
    • (2009) CNS Drugs , vol.23 , pp. 369-77
    • Debattista, C.1    Hawkins, J.2
  • 11
    • 69949087539 scopus 로고    scopus 로고
    • Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials
    • Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-91
    • (2009) Am J Psychiatry , vol.166 , pp. 980-91
    • Nelson, J.C.1    Papakostas, G.I.2
  • 12
    • 71449089682 scopus 로고    scopus 로고
    • Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: A review of registration trials
    • McIntyre RS, Muzina DJ, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 2009;10:3061-75
    • (2009) Expert Opin Pharmacother , vol.10 , pp. 3061-75
    • McIntyre, R.S.1    Muzina, D.J.2    Adams, A.3
  • 13
    • 77956421518 scopus 로고    scopus 로고
    • Quetiapine XR: Current status for the treatment of major depressive disorder
    • Pae CU, Sohi MS, Seo HJ, et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1165-73
    • (2010) Prog Neuropsychopharmacol Biol Psychiatry , vol.34 , pp. 1165-73
    • Pae, C.U.1    Sohi, M.S.2    Seo, H.J.3
  • 14
    • 0019976616 scopus 로고
    • Major tranquillisers used as antidepressants. A review
    • Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord 1982;4:173-93
    • (1982) J Affect Disord , vol.4 , pp. 173-93
    • Robertson, M.M.1    Trimble, M.R.2
  • 15
    • 0035902983 scopus 로고    scopus 로고
    • Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile
    • Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201
    • (2001) Eur J Pharmacol , vol.425 , pp. 197-201
    • Schmidt, A.W.1    Lebel, L.A.2    Howard Jr., H.R.3    Zorn, S.H.4
  • 16
    • 29344438343 scopus 로고    scopus 로고
    • Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety
    • Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):30-40
    • (2005) J Clin Psychiatry , vol.66 , Issue.SUPPL. 8 , pp. 30-40
    • Blier, P.1    Szabo, S.T.2
  • 18
    • 54049141721 scopus 로고    scopus 로고
    • Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection
    • Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008;60:358-403
    • (2008) Pharmacol Rev , vol.60 , pp. 358-403
    • Lieberman, J.A.1    Bymaster, F.P.2    Meltzer, H.Y.3
  • 19
    • 0034049108 scopus 로고    scopus 로고
    • Depression: The case for a monoamine deficiency
    • Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000;61(Suppl 6):7-11
    • (2000) J Clin Psychiatry , vol.61 , Issue.SUPPL. 6 , pp. 7-11
    • Delgado, P.L.1
  • 20
    • 60149086219 scopus 로고    scopus 로고
    • Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A
    • Shelton RC, Sanders-Bush E, Manier DH, Lewis DA. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 2009;158:1406-15
    • (2009) Neuroscience , vol.158 , pp. 1406-15
    • Shelton, R.C.1    Sanders-Bush, E.2    Manier, D.H.3    Lewis, D.A.4
  • 21
    • 73549116494 scopus 로고    scopus 로고
    • 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants
    • Richardson-Jones JW, Craige CP, Guiard BP, et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010;65:40-52
    • (2010) Neuron , vol.65 , pp. 40-52
    • Richardson-Jones, J.W.1    Craige, C.P.2    Guiard, B.P.3
  • 22
    • 2142715377 scopus 로고    scopus 로고
    • How antidepressants help depression: Mechanisms of action and clinical response
    • Delgado PL. How antidepressants help depression: mechanisms of action and clinical response. J Clin Psychiatry 2004;65(Suppl 4):25-30
    • (2004) J Clin Psychiatry , vol.65 , Issue.SUPPL. 4 , pp. 25-30
    • Delgado, P.L.1
  • 23
    • 0034635825 scopus 로고    scopus 로고
    • SNaRIs NaSSAs and NaRIs: New agents for the treatment of depression
    • Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-18
    • (2000) Lancet , vol.355 , pp. 911-18
    • Kent, J.M.1
  • 24
    • 0041932292 scopus 로고    scopus 로고
    • The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways
    • Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
    • (2003) J Pharmacol Exp Ther , vol.306 , pp. 954-64
    • Millan, M.J.1    Gobert, A.2    Lejeune, F.3
  • 25
    • 72149119722 scopus 로고    scopus 로고
    • A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: Approaching early-onset antidepressants
    • Pandey DK, Mahesh R, Kumar AA, et al. A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol Biochem Behav 2010;94:363-73
    • (2010) Pharmacol Biochem Behav , vol.94 , pp. 363-73
    • Pandey, D.K.1    Mahesh, R.2    Kumar, A.A.3
  • 26
    • 4444260616 scopus 로고    scopus 로고
    • The therapeutic role of 5-HT1A and 5-HT2A receptors in depression
    • Celada P, Puig M, Amargos-Bosch M, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252-65
    • (2004) J Psychiatry Neurosci , vol.29 , pp. 252-65
    • Celada, P.1    Puig, M.2    Amargos-Bosch, M.3
  • 27
    • 1642293910 scopus 로고    scopus 로고
    • The selective norepinephrine reuptake inhibitor antidepressant reboxetine: Pharmacological and clinical profile
    • Hajos M, Fleishaker JC, Filipiak-Reisner JK, et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004;10:23-44
    • (2004) CNS Drug Rev , vol.10 , pp. 23-44
    • Hajos, M.1    Fleishaker, J.C.2    Filipiak-Reisner, J.K.3
  • 29
    • 0034007549 scopus 로고    scopus 로고
    • Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
    • Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65
    • (2000) Depress Anxiety , vol.11 , pp. 58-65
    • Corrigan, M.H.1    Denahan, A.Q.2    Wright, C.E.3
  • 30
    • 1542344432 scopus 로고    scopus 로고
    • Ziprasidone: A novel psychotropic with unique properties
    • Ballas C, Yang C, O'Reardon J, et al. Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004;4:179-86
    • (2004) Expert Rev Neurother , vol.4 , pp. 179-86
    • Ballas, C.1    Yang, C.2    O'Reardon, J.3
  • 31
    • 49549104014 scopus 로고    scopus 로고
    • N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity
    • Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33:2303-12
    • (2008) Neuropsychopharmacology , vol.33 , pp. 2303-12
    • Jensen, N.H.1    Rodriguiz, R.M.2    Caron, M.G.3
  • 33
    • 68949141678 scopus 로고    scopus 로고
    • Antipsychotic drug actions on gene modulation and signaling mechanisms
    • Molteni R, Calabrese F, Racagni G, et al. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 2009;124:74-85
    • (2009) Pharmacol Ther , vol.124 , pp. 74-85
    • Molteni, R.1    Calabrese, F.2    Racagni, G.3
  • 34
    • 0037215386 scopus 로고    scopus 로고
    • Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs
    • Bai O, Chlan-Fourney J, Bowen R, et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003;71:127-31
    • (2003) J Neurosci Res , vol.71 , pp. 127-31
    • Bai, O.1    Chlan-Fourney, J.2    Bowen, R.3
  • 35
    • 2342451962 scopus 로고    scopus 로고
    • Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus
    • Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004;1010:81-6
    • (2004) Brain Res , vol.1010 , pp. 81-6
    • Bai, O.1    Zhang, H.2    Li, X.M.3
  • 36
    • 27744496919 scopus 로고    scopus 로고
    • Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress
    • Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005;1063:32-9
    • (2005) Brain Res , vol.1063 , pp. 32-9
    • Luo, C.1    Xu, H.2    Li, X.M.3
  • 37
    • 77649274917 scopus 로고    scopus 로고
    • Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression
    • Yoshimura R, Ikenouchi-Sugita A, Hori H, et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:308-12
    • (2010) Prog Neuropsychopharmacol Biol Psychiatry , vol.34 , pp. 308-12
    • Yoshimura, R.1    Ikenouchi-Sugita, A.2    Hori, H.3
  • 38
    • 41949107744 scopus 로고    scopus 로고
    • Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence
    • Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22:367-88
    • (2008) CNS Drugs , vol.22 , pp. 367-88
    • Pae, C.U.1    Serretti, A.2    Patkar, A.A.3    Masand, P.S.4
  • 40
    • 34347335477 scopus 로고    scopus 로고
    • The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study
    • Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53
    • (2007) J Clin Psychiatry , vol.68 , pp. 843-53
    • Berman, R.M.1    Marcus, R.N.2    Swanink, R.3
  • 41
    • 40949089056 scopus 로고    scopus 로고
    • The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study
    • Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-65
    • (2008) J Clin Psychopharmacol , vol.28 , pp. 156-65
    • Marcus, R.N.1    McQuade, R.D.2    Carson, W.H.3
  • 42
    • 0018425438 scopus 로고
    • A new depression scale designed to be sensitive to change
    • Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
    • (1979) Br J Psychiatry , vol.134 , pp. 382-9
    • Montgomery, S.A.1    Asberg, M.2
  • 45
    • 71649092568 scopus 로고    scopus 로고
    • Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies
    • Nelson JC, Mankoski R, Baker RA, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord 2010;120:133-40
    • (2010) J Affect Disord , vol.120 , pp. 133-40
    • Nelson, J.C.1    Mankoski, R.2    Baker, R.A.3
  • 46
    • 60349130186 scopus 로고    scopus 로고
    • Adjunctive aripiprazole in major depressive disorder: Analysis of efficacy and safety in patients with anxious and atypical features
    • Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 2008;69:1928-36
    • (2008) J Clin Psychiatry , vol.69 , pp. 1928-36
    • Trivedi, M.H.1    Thase, M.E.2    Fava, M.3
  • 47
    • 66849141289 scopus 로고    scopus 로고
    • Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants
    • Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197-206
    • (2009) CNS Spectr , vol.14 , pp. 197-206
    • Berman, R.M.1    Fava, M.2    Thase, M.E.3
  • 48
    • 0027439117 scopus 로고
    • Quality of life enjoyment and satisfaction questionnaire: A new measure
    • Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6
    • (1993) Psychopharmacol Bull , vol.29 , pp. 321-6
    • Endicott, J.1    Nee, J.2    Harrison, W.3    Blumenthal, R.4
  • 49
    • 38349106715 scopus 로고    scopus 로고
    • Aripiprazole monotherapy in nonpsychotic bipolar i depression: Results of 2 randomized, placebo-controlled studies
    • Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
    • (2008) J Clin Psychopharmacol , vol.28 , pp. 13-20
    • Thase, M.E.1    Jonas, A.2    Khan, A.3
  • 50
    • 77954138432 scopus 로고    scopus 로고
    • Safety and tolerability of adjunctive aripiprazole in major depressive disorder: A pooled post hoc analysis (studies CN138-139 and CN138-163)
    • Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 2009;11:344-52
    • (2009) Prim Care Companion J Clin Psychiatry , vol.11 , pp. 344-52
    • Nelson, J.C.1    Thase, M.E.2    Trivedi, M.H.3
  • 51
    • 68449095067 scopus 로고    scopus 로고
    • Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies
    • Fava M, Wisniewski SR, Thase ME, et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol 2009;29:362-7
    • (2009) J Clin Psychopharmacol , vol.29 , pp. 362-7
    • Fava, M.1    Wisniewski, S.R.2    Thase, M.E.3
  • 52
    • 77954679900 scopus 로고    scopus 로고
    • Safety considerations of the use of second generation antipsychotics in the treatment of major depression: Extrapyramidal and metabolic side effects
    • Debattista C, Debattista K. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr Drug Saf 2010;5:263-6
    • (2010) Curr Drug Saf , vol.5 , pp. 263-6
    • Debattista, C.1    Debattista, K.2
  • 53
    • 70449704967 scopus 로고    scopus 로고
    • Olanzapine and fluoxetine combination therapy for treatment-resistant depression: Review of efficacy, safety, and study design issues
    • Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat 2009;5:369-83
    • (2009) Neuropsychiatr Dis Treat , vol.5 , pp. 369-83
    • Bobo, W.V.1    Shelton, R.C.2
  • 54
    • 76949088866 scopus 로고    scopus 로고
    • Olanzapine/ fluoxetine: A review of its use in patients with treatment-resistant major depressive disorder
    • Croxtall JD, Scott LJ. Olanzapine/ fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010;24:245-62
    • (2010) CNS Drugs , vol.24 , pp. 245-62
    • Croxtall, J.D.1    Scott, L.J.2
  • 55
    • 0035169876 scopus 로고    scopus 로고
    • A novel augmentation strategy for treating resistant major depression
    • Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4
    • (2001) Am J Psychiatry , vol.158 , pp. 131-4
    • Shelton, R.C.1    Tollefson, G.D.2    Tohen, M.3
  • 56
    • 27544509056 scopus 로고    scopus 로고
    • Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance
    • Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:1289-97
    • (2005) J Clin Psychiatry , vol.66 , pp. 1289-97
    • Shelton, R.C.1    Williamson, D.J.2    Corya, S.A.3
  • 57
    • 33750374140 scopus 로고    scopus 로고
    • A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression
    • Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-72
    • (2006) Depress Anxiety , vol.23 , pp. 364-72
    • Corya, S.A.1    Williamson, D.2    Sanger, T.M.3
  • 58
    • 33847681848 scopus 로고    scopus 로고
    • A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    • Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224-36
    • (2007) J Clin Psychiatry , vol.68 , pp. 224-36
    • Thase, M.E.1    Corya, S.A.2    Osuntokun, O.3
  • 59
    • 3242716826 scopus 로고    scopus 로고
    • A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features
    • Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004;24:365-73
    • (2004) J Clin Psychopharmacol , vol.24 , pp. 365-73
    • Rothschild, A.J.1    Williamson, D.J.2    Tohen, M.F.3
  • 60
    • 68149125187 scopus 로고    scopus 로고
    • A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The study of pharmacotherapy of psychotic depression (STOP-PD)
    • Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009;66:838-47
    • (2009) Arch Gen Psychiatry , vol.66 , pp. 838-47
    • Meyers, B.S.1    Flint, A.J.2    Rothschild, A.J.3
  • 61
    • 0026877917 scopus 로고
    • The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
    • Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
    • (1992) Med Care , vol.30 , pp. 473-83
    • Ware Jr., J.E.1    Sherbourne, C.D.2
  • 62
    • 64149130671 scopus 로고    scopus 로고
    • An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression
    • Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009;70:387-96
    • (2009) J Clin Psychiatry , vol.70 , pp. 387-96
    • Trivedi, M.H.1    Thase, M.E.2    Osuntokun, O.3
  • 63
    • 77951058334 scopus 로고    scopus 로고
    • Olanzapine/fluoxetine combination in patients with treatment-resistant depression: Rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies
    • Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010;71:451-62
    • (2010) J Clin Psychiatry , vol.71 , pp. 451-62
    • Tohen, M.1    Case, M.2    Trivedi, M.H.3
  • 64
    • 33646501208 scopus 로고    scopus 로고
    • Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis
    • Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 2006;188:410-5
    • (2006) Br J Psychiatry , vol.188 , pp. 410-5
    • Wijkstra, J.1    Lijmer, J.2    Balk, F.J.3
  • 65
    • 16844384048 scopus 로고    scopus 로고
    • Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone?
    • Parker G, Brotchie H, Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? Am J Psychiatry 2005;162:796-8
    • (2005) Am J Psychiatry , vol.162 , pp. 796-8
    • Parker, G.1    Brotchie, H.2    Parker, K.3
  • 66
    • 0344551192 scopus 로고    scopus 로고
    • Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study
    • Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003;64:1349-56
    • (2003) J Clin Psychiatry , vol.64 , pp. 1349-56
    • Corya, S.A.1    Andersen, S.W.2    Detke, H.C.3
  • 67
    • 10744220918 scopus 로고    scopus 로고
    • Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar i depression
    • Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
    • (2003) Arch Gen Psychiatry , vol.60 , pp. 1079-88
    • Tohen, M.1    Vieta, E.2    Calabrese, J.3
  • 68
    • 28844469344 scopus 로고    scopus 로고
    • Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder
    • Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 2005;66:1468-76
    • (2005) J Clin Psychiatry , vol.66 , pp. 1468-76
    • Andersen, S.W.1    Clemow, D.B.2    Corya, S.A.3
  • 69
    • 36049015484 scopus 로고    scopus 로고
    • Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study
    • McIntyre A, Gendron A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007;24:487-94
    • (2007) Depress Anxiety , vol.24 , pp. 487-94
    • McIntyre, A.1    Gendron, A.2
  • 70
    • 54449093654 scopus 로고    scopus 로고
    • A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
    • Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008;23:269-75
    • (2008) Int Clin Psychopharmacol , vol.23 , pp. 269-75
    • Garakani, A.1    Martinez, J.M.2    Marcus, S.3
  • 71
    • 66349134744 scopus 로고    scopus 로고
    • Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study
    • Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9
    • (2009) J Clin Psychiatry , vol.70 , pp. 540-9
    • Bauer, M.1    Pretorius, H.W.2    Constant, E.L.3
  • 72
    • 77956440952 scopus 로고    scopus 로고
    • Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study
    • El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010;13:917-32
    • (2010) Int J Neuropsychopharmacol , vol.13 , pp. 917-32
    • El-Khalili, N.1    Joyce, M.2    Atkinson, S.3
  • 73
    • 53149092475 scopus 로고    scopus 로고
    • The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial
    • Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 2008;8:73
    • (2008) BMC Psychiatry , vol.8 , pp. 73
    • Chaput, Y.1    Magnan, A.2    Gendron, A.3
  • 74
    • 70149093635 scopus 로고    scopus 로고
    • Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study
    • Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009;14:299-313
    • (2009) CNS Spectr , vol.14 , pp. 299-313
    • Weisler, R.1    Joyce, M.2    McGill, L.3
  • 75
    • 66349094570 scopus 로고    scopus 로고
    • Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo- and duloxetine-controlled study
    • Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-39
    • (2009) J Clin Psychiatry , vol.70 , pp. 526-39
    • Cutler, A.J.1    Montgomery, S.A.2    Feifel, D.3
  • 76
    • 78649676124 scopus 로고    scopus 로고
    • Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study
    • published online 9 August 2010, doi:10.1016/j.jad.2010.06.031
    • Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2010:published online 9 August 2010 doi:10.1016/j.jad.2010.06.031
    • (2010) J Affect Disord
    • Bortnick, B.1    El-Khalili, N.2    Banov, M.3
  • 77
    • 78649524734 scopus 로고    scopus 로고
    • Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD)
    • Vienna Austria
    • Earley W, McIntyre A, Wang G, et al. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). 8th International Forum on Mood and Anxiety Disorders. Vienna, Austria; 2008. p. P10
    • (2008) 8th International Forum on Mood and Anxiety Disorders
    • Earley, W.1    McIntyre, A.2    Wang, G.3
  • 78
    • 78649522704 scopus 로고    scopus 로고
    • Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD)
    • Vienna Austria
    • Katila H, Mezhebovsky I, Mulroy A, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD). 8th International Forum on Mood and Anxiety Disorders. Vienna, Austria; 2008. p. P23
    • (2008) 8th International Forum on Mood and Anxiety Disorders
    • Katila, H.1    Mezhebovsky, I.2    Mulroy, A.3
  • 79
    • 78649499136 scopus 로고    scopus 로고
    • Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: A randomized, placebo-controlled trial
    • Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010;27:964-76
    • (2010) Depress Anxiety , vol.27 , pp. 964-76
    • Liebowitz, M.1    Lam, R.W.2    Lepola, U.3
  • 80
    • 76449083788 scopus 로고    scopus 로고
    • Treatment of unipolar psychotic depression: A randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine
    • Wijkstra J, Burger H, van den Broek WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010;121:190-200
    • (2010) Acta Psychiatr Scand , vol.121 , pp. 190-200
    • Wijkstra, J.1    Burger, H.2    Van Den Broek, W.W.3
  • 81
    • 41549159758 scopus 로고    scopus 로고
    • Quetiapine monotherapy for bipolar depression
    • Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat 2008;4:11-21
    • (2008) Neuropsychiatr Dis Treat , vol.4 , pp. 11-21
    • Thase, M.E.1
  • 82
    • 77953500268 scopus 로고    scopus 로고
    • Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study
    • Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13:305-20
    • (2010) Int J Neuropsychopharmacol , vol.13 , pp. 305-20
    • Bandelow, B.1    Chouinard, G.2    Bobes, J.3
  • 83
    • 70349337426 scopus 로고    scopus 로고
    • Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders
    • Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009;9:1147-58
    • (2009) Expert Rev Neurother , vol.9 , pp. 1147-58
    • Gao, K.1    Sheehan, D.V.2    Calabrese, J.R.3
  • 84
    • 33750212103 scopus 로고    scopus 로고
    • Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
    • Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006;31:2505-13
    • (2006) Neuropsychopharmacology , vol.31 , pp. 2505-13
    • Rapaport, M.H.1    Gharabawi, G.M.2    Canuso, C.M.3
  • 85
    • 38449106889 scopus 로고    scopus 로고
    • Risperidone for treatment-refractory major depressive disorder: A randomized trial
    • Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007;147:593-602
    • (2007) Ann Intern Med , vol.147 , pp. 593-602
    • Mahmoud, R.A.1    Pandina, G.J.2    Turkoz, I.3
  • 86
    • 38549087763 scopus 로고    scopus 로고
    • Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression
    • Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008;16:21-30
    • (2008) Am J Geriatr Psychiatry , vol.16 , pp. 21-30
    • Alexopoulos, G.S.1    Canuso, C.M.2    Gharabawi, G.M.3
  • 87
    • 49649096422 scopus 로고    scopus 로고
    • Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study
    • Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:1228-336
    • (2008) J Clin Psychiatry , vol.69 , pp. 1228-336
    • Reeves, H.1    Batra, S.2    May, R.S.3
  • 88
    • 57749198414 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression
    • Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009;43:205-14
    • (2009) J Psychiatr Res , vol.43 , pp. 205-14
    • Keitner, G.I.1    Garlow, S.J.2    Ryan, C.E.3
  • 89
  • 90
    • 49549104016 scopus 로고    scopus 로고
    • Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation'
    • author reply 2548
    • Carroll BJ. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation'. Neuropsychopharmacology 2008;33:2546-7; author reply 2548
    • (2008) Neuropsychopharmacology , vol.33 , pp. 2546-7
    • Carroll, B.J.1
  • 91
    • 55849129650 scopus 로고    scopus 로고
    • Ziprasidone in the treatment of affective disorders: A review
    • Rosa AR, Franco C, Torrent C, et al. Ziprasidone in the treatment of affective disorders: a review. CNS Neurosci Ther 2008;14:278-86
    • (2008) CNS Neurosci Ther , vol.14 , pp. 278-86
    • Rosa, A.R.1    Franco, C.2    Torrent, C.3
  • 92
    • 1842855918 scopus 로고    scopus 로고
    • Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder
    • Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217-21
    • (2004) J Clin Psychiatry , vol.65 , pp. 217-21
    • Papakostas, G.I.1    Petersen, T.J.2    Nierenberg, A.A.3
  • 93
    • 34548299095 scopus 로고    scopus 로고
    • Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study
    • Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007;68:1071-7
    • (2007) J Clin Psychiatry , vol.68 , pp. 1071-7
    • Dunner, D.L.1    Amsterdam, J.D.2    Shelton, R.C.3
  • 94
    • 0036047459 scopus 로고    scopus 로고
    • World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder
    • Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43
    • (2002) World J Biol Psychiatry , vol.3 , pp. 5-43
    • Bauer, M.1    Whybrow, P.C.2    Angst, J.3
  • 95
    • 34247890186 scopus 로고    scopus 로고
    • World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care
    • Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007;8:67-104
    • (2007) World J Biol Psychiatry , vol.8 , pp. 67-104
    • Bauer, M.1    Bschor, T.2    Pfennig, A.3
  • 96
  • 97
    • 70350051602 scopus 로고    scopus 로고
    • London, UK: National Institute for Health and Clinical Excellence Available from [Last accessed 6 November 2010]
    • Depression: the treatment and management of depression in adults. London, UK: National Institute for Health and Clinical Excellence. 2009. Available from: www.nice.org.uk/ CG90 [Last accessed 6 November 2010]
    • (2009) Depression: The Treatment and Management of Depression in Adults
  • 98
    • 69649095792 scopus 로고    scopus 로고
    • Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy
    • Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-43
    • (2009) J Affect Disord , vol.117 , Issue.SUPPL. 1
    • Lam, R.W.1    Kennedy, S.H.2    Grigoriadis, S.3
  • 99
    • 77951226602 scopus 로고    scopus 로고
    • Major depressive disorder treatment guidelines in America and Europe
    • Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010;71(Suppl E1):e04
    • (2010) J Clin Psychiatry , vol.71 , Issue.SUPPL. E1
    • Davidson, J.R.1
  • 101
    • 40949136198 scopus 로고    scopus 로고
    • Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review
    • Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28:203-9
    • (2008) J Clin Psychopharmacol , vol.28 , pp. 203-9
    • Gao, K.1    Kemp, D.E.2    Ganocy, S.J.3
  • 102
    • 67049162787 scopus 로고    scopus 로고
    • Akathisia: An updated review focusing on second-generation antipsychotics
    • Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70:627-43
    • (2009) J Clin Psychiatry , vol.70 , pp. 627-43
    • Kane, J.M.1    Fleischhacker, W.W.2    Hansen, L.3
  • 103
    • 77649217019 scopus 로고    scopus 로고
    • Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies
    • Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010;67:220-9
    • (2010) Arch Gen Psychiatry , vol.67 , pp. 220-9
    • Luppino, F.S.1    De Wit, L.M.2    Bouvy, P.F.3
  • 104
    • 59749102688 scopus 로고    scopus 로고
    • Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap
    • McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009;9:51-9
    • (2009) Curr Diab Rep , vol.9 , pp. 51-9
    • McIntyre, R.S.1    Rasgon, N.L.2    Kemp, D.E.3
  • 105
    • 68149182296 scopus 로고    scopus 로고
    • Major depression and coronary artery disease in the Swedish twin registry: Phenotypic, genetic, and environmental sources of comorbidity
    • Kendler KS, Gardner CO, Fiske A, Gatz M. Major depression and coronary artery disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of comorbidity. Arch Gen Psychiatry 2009;66:857-63
    • (2009) Arch Gen Psychiatry , vol.66 , pp. 857-63
    • Kendler, K.S.1    Gardner, C.O.2    Fiske, A.3    Gatz, M.4
  • 106
    • 3342901698 scopus 로고    scopus 로고
    • Physical health monitoring of patients with schizophrenia
    • Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
    • (2004) Am J Psychiatry , vol.161 , pp. 1334-49
    • Marder, S.R.1    Essock, S.M.2    Miller, A.L.3
  • 107
    • 0037227192 scopus 로고    scopus 로고
    • Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)
    • Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
    • (2003) Arch Gen Psychiatry , vol.60 , pp. 82-91
    • Meltzer, H.Y.1    Alphs, L.2    Green, A.I.3
  • 108
    • 33845934245 scopus 로고    scopus 로고
    • Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: A retrospective database study
    • Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006;28:1912-21
    • (2006) Clin Ther , vol.28 , pp. 1912-21
    • Ward, A.1    Ishak, K.2    Proskorovsky, I.3    Caro, J.4
  • 109
    • 33747185865 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study
    • Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333(7561):224
    • (2006) BMJ , vol.333 , Issue.7561 , pp. 224
    • Tiihonen, J.1    Wahlbeck, K.2    Lonnqvist, J.3
  • 110
    • 34447133528 scopus 로고    scopus 로고
    • Safety and usage of atypical antipsychotic medicines in children: A nationwide prospective cohort study
    • Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf 2007;30:569-79
    • (2007) Drug Saf , vol.30 , pp. 569-79
    • Harrison-Woolrych, M.1    Garcia-Quiroga, J.2    Ashton, J.3    Herbison, P.4
  • 111
    • 26844538114 scopus 로고    scopus 로고
    • Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials
    • Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43
    • (2005) JAMA , vol.294 , pp. 1934-43
    • Schneider, L.S.1    Dagerman, K.S.2    Insel, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.